Effects of Costovertebral Joint Mobilization on Respiratory Function in Asthmatic Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthmatic
- Sponsor
- Riphah International University
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Assessment of respiratory function FEV1 using spirometer.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this randomized controlled trial is to determine the effectiveness of costovertebral joint mobilization on lung function in asthmatics. By targeting the thoracic region, costovertebral mobilization can play a valuable role in enhancing respiratory function and improving the overall well-being of individuals with respiratory conditions.
Detailed Description
Costovertebral joint mobilization can help to improve this by increasing the mobility of the ribs and thoracic spine, which can help to expand the chest and improve lung function. Additionally, costovertebral joint mobilization can help to reduce muscle tension in the chest and upper back, which can also contribute to improved respiratory function. This is because tense or tight muscles can restrict the movement of the rib cage, limiting the ability of the lungs to expand and contract. Mobilization are performed in three positions, sitting, supine lying and side lying with arm abducted of the side to be mobilized. The improvement by regular physical training of breathing technique and chest wall mechanics may be explained by mobilization of the costovertebral articulations.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Force Expiratory Volume 1/Force Vital Capacity ratio less than 0.7
- •Mild asthma (Force Expiratory Volume 1 over 70% predicted)
- •Chest tightness (inspiratory muscle tightness)
- •Altered Dyspnea index.
Exclusion Criteria
- •presence of any underlying lung condition other than asthma.
- •significant cardiovascular or musculoskeletal disease that may compromise the participant's capacity to participate in physical activity;
- •active cancer.
- •uncontrolled hypertension or diabetes.
Outcomes
Primary Outcomes
Assessment of respiratory function FEV1 using spirometer.
Time Frame: 3 weeks
Spirometry is one of the Pulmonary Function Test; they are useful investigations in the management of patients with respiratory disease or respiratory weakness secondary to neurological impairment. Spirometry will measure FEV1
Tape for chest expansion
Time Frame: 3 weeks
Chest expansion is measured using a measuring tape at 2 different levels of the rib cage. The 2 measurements of chest diameter are taken at the end of deep inspiratory and expiratory maneuvers. Upper and lower chest expansion are obtained by subtracting the inspiratory diameter from the expiratory diameter, according to the designated anatomical markers. The assessment is performed 1 measurement of upper chest expansion and then 1 measurement of the lower chest expansion consecutively, holding the measuring tape at both ends with thumb and index finger around the patient body.
Dyspnea index
Time Frame: 3 weeks
It is used to describe their sense of breathlessness and breathing problem, and the effects of their breathing on their lives.
Assessment of respiratory function FVC using spirometer.
Time Frame: 3 weeks
Spirometry is one of the Pulmonary Function Test; they are useful investigations in the management of patients with respiratory disease or respiratory weakness secondary to neurological impairment. Spirometry will measure FVC